[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 113, "companyOfficers": [{"maxAge": 1, "name": "Dr. June S. Almenoff FACP, M.D., Ph.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.555, "open": 0.5537, "dayLow": 0.5523, "dayHigh": 0.57, "regularMarketPreviousClose": 0.555, "regularMarketOpen": 0.5537, "regularMarketDayLow": 0.5523, "regularMarketDayHigh": 0.57, "beta": 3.464, "forwardPE": 18.476667, "volume": 636150, "regularMarketVolume": 636150, "averageVolume": 1967038, "averageVolume10days": 967930, "averageDailyVolume10Day": 967930, "bid": 0.5546, "ask": 0.56, "bidSize": 1200, "askSize": 800, "marketCap": 16464373, "fiftyTwoWeekLow": 0.257, "fiftyTwoWeekHigh": 8.68, "priceToSalesTrailing12Months": 0.46060634, "fiftyDayAverage": 0.8634, "twoHundredDayAverage": 1.044445, "currency": "USD", "enterpriseValue": 704521792, "profitMargins": 0.32374, "floatShares": 1199542900, "sharesOutstanding": 29703000, "sharesShort": 615654, "sharesShortPriorMonth": 305715, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0207, "heldPercentInstitutions": 0.06702, "shortRatio": 0.27, "shortPercentOfFloat": 0.0208, "impliedSharesOutstanding": 11070800, "bookValue": 1.086, "priceToBook": 0.5104052, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": 11572000, "trailingEps": -8.0, "forwardEps": 0.03, "lastSplitFactor": "1:40", "lastSplitDate": 1679529600, "enterpriseToRevenue": 19.71, "enterpriseToEbitda": -29.272, "52WeekChange": -0.93392855, "SandP52WeekChange": 0.27220368, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RDHL", "underlyingSymbol": "RDHL", "shortName": "Redhill Biopharma Ltd.", "longName": "RedHill Biopharma Ltd.", "firstTradeDateEpochUtc": 1357569000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "55b47776-7c51-3ec7-bc27-c300c5d6081d", "messageBoardId": "finmb_104926324", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.5543, "targetHighPrice": 760.0, "targetLowPrice": 760.0, "targetMeanPrice": 760.0, "targetMedianPrice": 760.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 7014000, "totalCashPerShare": 0.005, "ebitda": -24068000, "totalDebt": 2284000, "quickRatio": 0.352, "currentRatio": 0.96, "totalRevenue": 35745000, "debtToEquity": 65.802, "revenuePerShare": 14.516, "returnOnAssets": -0.1717, "freeCashflow": -38703624, "operatingCashflow": -26224000, "revenueGrowth": -0.902, "grossMargins": 0.42742002, "ebitdaMargins": -0.67332, "operatingMargins": -2.45434, "financialCurrency": "USD", "trailingPegRatio": null}]